Hematology

Castellucci and colleagues identified that a primary-outcome event had occurred in 44 (3.3%) of the 1,345 patients taking apixaban, compared to 96 (7.1%) of the 1,355 in the rivaroxaban group.

A large retrospective study identified risk factors for CNS relapse after transplant in adults with acute lymphoblastic leukaemia, highlighting elevated risk in Philadelphia chromosome positive disease.

A study identifies the ribosome biogenesis factor MYBBP1A as essential for acute myeloid leukaemia cell growth, revealing a potential therapeutic vulnerability.

Analysis of patient liver biopsies and cell models suggests epigenetic silencing may limit durability of AAV gene therapy, offering insight into long term variability in haemophilia treatment.

A transcriptional classifier identifies tumour reactive T cells in multiple myeloma and predicts response to immunotherapy, offering a potential biomarker for treatment selection.

A new study identifies a paralog dependency regulating MEF2C stability in acute myeloid leukaemia and demonstrates a peptide approach that suppresses disease progression in preclinical models.

Modelling across seven African countries shows malaria in pregnancy remains a major cause of maternal anaemia, with over 2 million cases projected in 2023.

Multi omics analysis shows ultra running drives inflammatory and oxidative red blood cell damage, impairing deformability and accelerating ageing.